Kawamura, Yasuo, Kihara, Mikihiro, Nishimoto, Kazuhiro et al. · Pathophysiology : the official journal of the International Society for Pathophysiology · 2003 · DOI
This small study looked at three ME/CFS patients who had problems with both nerve-muscle communication and autonomic nervous system dysfunction (how the body regulates heart rate, sweating, and other automatic functions). All three patients improved significantly when given low doses of a medication called pyridostigmine, which helps acetylcholine (a chemical messenger in the nervous system) work better. The authors suggest that some ME/CFS fatigue might be caused by a combination of these two problems working together.
This study provides preliminary evidence that some ME/CFS symptoms may stem from objective physiological defects in neuromuscular and autonomic function—defects that may be treatable with existing medications. If validated in larger studies, this could identify a physiological subgroup of ME/CFS patients who might benefit from targeted pharmacological intervention, moving the field toward mechanism-based treatment strategies.
This case series does not prove that pyridostigmine is effective for ME/CFS broadly, nor that neuromuscular transmission defects cause CFS in the general population—only that these three patients showed the findings and responded to treatment. There is no control group to account for placebo effect, and the small sample size means results cannot be generalized. Correlation between these physiological findings and CFS symptoms does not establish causation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →